We are a private biopharmaceutical company developing therapies for ocular disorders

Press Releases

Quethera will present pre-clinical efficacy data at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Baltimore, MD (7th-10 May 2017).

Quethera will present pre-clinical efficacy data at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Baltimore, MD (7th-10 May).

ARVO is the biggest eye research meeting in the world and the team will present evidence that the Quethera glaucoma gene therapy construct significantly enhances retinal ganglion cell survival after optic nerve injury. Two poster presentations from the Quethera team will outline the work which led to the design of the novel gene therapy construct and Prof. Keith Martin will deliver an oral presentation in the plenery Neuroprotection session showing the safety and efficacy of the Quethera construct in glaucoma animal models".